Soleus Capital Management L.P. Purchases 680,000 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Soleus Capital Management L.P. raised its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 136.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,180,000 shares of the company’s stock after acquiring an additional 680,000 shares during the period. Soleus Capital Management L.P.’s holdings in Takeda Pharmaceutical were worth $15,623,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. QRG Capital Management Inc. increased its position in shares of Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock valued at $4,364,000 after acquiring an additional 47,490 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Takeda Pharmaceutical by 48.6% in the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company’s stock valued at $600,000 after purchasing an additional 14,831 shares in the last quarter. US Bancorp DE increased its position in shares of Takeda Pharmaceutical by 21.2% during the 4th quarter. US Bancorp DE now owns 124,332 shares of the company’s stock worth $1,646,000 after purchasing an additional 21,744 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Takeda Pharmaceutical by 27.0% during the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company’s stock worth $205,000 after purchasing an additional 3,071 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Takeda Pharmaceutical by 60.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company’s stock valued at $2,409,000 after buying an additional 68,200 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.8%

Takeda Pharmaceutical stock opened at $14.11 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The company’s 50-day moving average is $14.76 and its 200-day moving average is $14.00. The firm has a market capitalization of $44.88 billion, a PE ratio of 35.26, a P/E/G ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.